BioBAY微信订阅号
BioPOS微信服务号
  • Number of enterprises    Total : 467

  • High-level Talents Projects


CMAB Biopharma holds a grand opening ceremony

time:03/29/2018 page views: resource:BioBAY

CMAB Biopharma Inc(CMAB), an all-round drug R&D and customized production service provider held a grand opening ceremony at Dushu Lake. In recent years, with the promotion of Marketing Authorization Holder (MAH) system in China, the demand for the high-quality contract development and manufacturing organization (CDMO) on the biopharmaceutical field is growing. CMAB Biopharma is committed to becoming a one-stop CDMO providing a full range of professional services for biological products ranging from the cell line establishment, process development, testing methods, GMP production to domestic and foreign declarations. At the same time, it provides customized services to customers based on their flexible needs.

Promote healthy growth of the industry through sustainable development


It is estimated that the global CDMO market scale will be over $90 billion in 2020, with the Chinese CDMO enterprises that have become the strategic suppliers of multinational pharmaceutical companies expected to play an increasingly important role in the market. According to statistics and prediction, from 2016 to 2020, the Chinese CDMO market scale will increase from RMB 27 billion to about RMB 52.8 billion with an average annual compound growth rate of 18.27%.

Liang Qibin 

Chairman of MAB Biopharma, China

In efforts to uphold customer-oriented principle, we are committed to manufacturing high-quality, safe and effective products. We have established a quality system that is fully compliant with international and domestic drug production and management regulations including the China Food and Drug Administration(CFDA), the US Food and Drug Administration (21 CFR), the European Drug Administration (Eudralex), WHO, PIC/S and ICH standards.

We will make huge inroads into MDMO based on the following three aspects:

First, we will guarantee the quality of CMC product.

Second, we will deliver the products on time.

Third, we will make the cost reasonable. In addition, we will pursue the best manufacturing conditions, materials and techniques instead of using inferior materials for vicious competition.

Explore the new direction of CDMO in a professional and flexible way


At present, some global leading CDMO enterprises are transferring from the traditional “Technology Transfer + Customization Production” mode into “Cooperative R&D + Customization Production” modem. Through this model, CDMO enterprises can on one hand, deeply participate in customers' innovation drug R & D from the early stage and pharmaceutical enterprises to promote the integration ofR&D, procurement, production among the whole supply chain. On the other hand, given the fact that CDMO enterprises cooperate with customers in the whole life cycle of innovative drugs, their technical concepts and management systems are gradually meshed with each other to form a deep strategic partnership.

Liang Qibin 

Chairman of MAB Biopharma, China

We are willing to cooperate with all biopharmaceutical companies which are seeking a new CDMO approach. As a comprehensive CDMO service provider, we will offer customers all-around services ranging from transforming DNA into finished products, such as the development of cell line, technique and analytical method, the clinical production of the preparation and API as well as the aseptic filling for clinical drugs. 

In addition, we are exploring a new business model and direction. Based on the advantage of having excellent teams and the distribution of the rare biological pharmaceutical human resource, we are planning to provide customized services to customers, help them speed up new drug R&D and market as well as minimize the repeated large-scale investment.

What’s more, we only provide CDMO services instead of unique business model on new drug business, in a bid to maximize customer’s patent protection as well as reduce conflicts with customers.

About CMAB Biopharma

CMAB Biopharma began its development in BioBay, a gathering place for new drug innovation, medical device and biotechnology industries with more than 460 high-tech start-ups. As an emerging enterprise in the CDMO field, CMAB with less than a-year history has been negotiating business cooperation with more than 20 customers, and in September this year it will start providing 200L, 500L, 1000L, and 2000L’s GMP clinical sample service and GMP filling service. In December 2017, it completed its A round financing with $38 million led by C-Bridge capital and participated by I-Bridge and Qianhai Fund Management.